The Centers for Medicare & Medicaid Services Aug. 15 released a state funding notice for the Cell and Gene Therapy Access Model. The CGT Access Model will test whether a CMS-led approach to developing and administering outcomes-based agreements for cell and gene therapies improves Medicaid beneficiaries’ health outcomes, broadens access to innovative treatment and reduces health care expenditures. It will initially focus on gene therapies for sickle cell disease. The notice includes an opportunity for applicants to apply for cooperative agreement funding to support participation in the CGT Access Model. Applicants must apply for participation in the model through a state applications request and apply for funding through the state funding notice, both of which are due Feb. 28, 2025. The award date is anticipated for July 1, 2025. 

Headline
The Department of Health and Human Services Administration for Community Living has launched the first phase of its Health at Home Challenge, a competition to…
Headline
The Medicaid and CHIP Payment and Access Commission approved recommendations it will issue to Congress in its June report on oversight and increased…
Headline
The AHA shared the following statement with the media in response to a report released May 7 by Families USA.   “This report is long on rhetoric and…
Headline
The AHA April 23 released a blog responding to a report issued April 22 by Paragon Health Institute. The blog highlights how the report relies on a long list…
Blog
Public
In think‑tank reports, like the one released this week by Paragon Health Institute, hospitals are often reduced to abstractions — payment rates, charts,…
Headline
The Centers for Medicare and Medicaid Services April 8 issued guidance on implementing a provision within the reconciliation bill passed in July 2025 regarding…